Mesothelioma News and Research RSS Feed - Mesothelioma News and Research

Mesothelioma is a form of cancer that is almost always caused by previous exposure to asbestos. In this disease, malignant cells develop in the mesothelium, a protective lining that covers most of the body's internal organs. Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles, or have been exposed to high levels of asbestos fibers.
New, authoritative website launched to educate people about mesothelioma

New, authoritative website launched to educate people about mesothelioma

Mesothelioma.us is a new and authoritative website that is devoted to educating people about the rare form of cancer, mesothelioma. For people who have been diagnosed with mesothelioma and their friends and loved ones who wish to know more about the disease and its treatment options, the new website is one-stop mesothelioma information stop. [More]
CANCER-ID consortium aims to set up standard procedures for clinical validation of blood-based biomarkers

CANCER-ID consortium aims to set up standard procedures for clinical validation of blood-based biomarkers

Blood-based biomarkers such as circulating tumor cells (CTCs), circulating free DNA (cfDNA), circulating tumor DNA (ctDNA) and microRNAs (miRNAs) are potential indicators for the tumor burden of patients living with cancer. [More]
Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania. [More]
SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug. [More]
Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

The Ben May Department for Cancer Research at the University of Chicago will hold a day-long symposium on cancer immunotherapy for physicians and researchers. [More]

Mesothelioma Victims Center now offers guidance for former power plant workers with mesothelioma

The Mesothelioma Victims Center is now making the best possible compensation a reality for former power plant workers who have been diagnosed with mesothelioma, because these types of individuals could qualify for multi-million dollar mesothelioma settlements. [More]
New NCCN Guidelines for treating Acute Lymphoblastic Leukemia

New NCCN Guidelines for treating Acute Lymphoblastic Leukemia

According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Acute Lymphoblastic Leukemia (ALL), the treatment approach to ALL is one of the most complex and intensive programs in cancer therapy. [More]

Mesothelioma Compensation Center educates individuals about mesothelioma compensation claim

The Mesothelioma Compensation Center is doing everything possible to educate all diagnosed victims of mesothelioma and their family members about the most critical component of a mesothelioma compensation claim that, believe it or not, comes down to the skill of the lawyer advancing the claim; especially if the diagnosed victim was exposed to asbestos in the automotive manufacturing or repair industry. [More]
Study finds higher levels of malignant mesothelioma cases in southern Nevada

Study finds higher levels of malignant mesothelioma cases in southern Nevada

Malignant mesothelioma has been found at higher than expected levels in women and in individuals younger than 55 years old in the southern Nevada counties of Clark and Nye, likewise in the same region carcinogenic mineral fibers including actinolite asbestos, erionite, winchite, magnesioriebeckite and richterite were discovered. [More]
Diagnosed US Navy veterans, shipyard workers provided instant access to top mesothelioma compensation lawyers

Diagnosed US Navy veterans, shipyard workers provided instant access to top mesothelioma compensation lawyers

The Mesothelioma Compensation Center is, once again, stepping up for diagnosed victims of mesothelioma exposed to asbestos while serving in the US Navy or at a shipyard, by making them a top priority when it comes to providing instant access to the nation's most skilled compensation attorneys because it is these individuals who deserve the best possible compensation. [More]

Discoveries suggest that asbestos may be more widespread in Nevada, Arizona

In 2011, geologists at the University of Nevada, Las Vegas, began discovering asbestos where none should be -- in granite rocks with a geologic history not previously known to produce asbestos. [More]

Mesothelioma Victims Center implores US homeowners to understand the potential hazards of asbestos

The Mesothelioma Victims Center is urging all US homeowners to familiarize themselves with the dangers of exposure to asbestos in any home constructed with the material as there could be a remote possibility of developing a malignant form of cancer called mesothelioma. [More]
EnGeneIC closes oversubscribed Series B financing

EnGeneIC closes oversubscribed Series B financing

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing. [More]
Next generation sequencing in malignant pleural mesothelioma tumors reveals complex mutational setting

Next generation sequencing in malignant pleural mesothelioma tumors reveals complex mutational setting

Next generation sequencing in malignant pleural mesothelioma (MPM) tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival and cell proliferation pathways. Increased accumulation of mutations correlates with early progression of the tumor and decreased survival. [More]
FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

A team led by Fengzhi Li, PhD, and Xinjiang Wang, PhD, of Roswell Park Cancer Institute has reported new findings regarding therapeutic targets of the novel anticancer agent FL118. Previous studies from these researchers have showed that FL118 induces cancer cell death, or apoptosis, by inhibiting expression of multiple cell-survival proteins (survivin, Mcl-1, XIAP or cIAP2). [More]
Medical experts to discuss Saatchi Bill at free public event

Medical experts to discuss Saatchi Bill at free public event

The Saatchi Bill claims that it will help doctors to innovate new treatments and cures, safely and responsibly, for cancer and other diseases. [More]
Curcumin and tackling mesothelioma: an interview with Dr. Afshin Dowlati

Curcumin and tackling mesothelioma: an interview with Dr. Afshin Dowlati

An important point about this work is that the research into curcumin was conducted following a discovery about mesothelioma, rather than being the primary endpoint of the study. [More]
Concordia Healthcare reports record revenues of 147% in third quarter 2014

Concordia Healthcare reports record revenues of 147% in third quarter 2014

Concordia Healthcare Corp. ("Concordia" or the "Company"), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and nine months ended September 30, 2014. [More]
Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there is currently no acceptable therapy. [More]
PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid. [More]
Advertisement
Advertisement